Conference Coverage

Tear proteins seen as Parkinson’s biomarker


 

FROM AAN 2018

Dr. Lew and his coinvestigators measured the levels of the protein alpha-synuclein in the tears of 55 people with PD and compared them with levels in the tears of 27 age- and sex-matched controls. They also measured oligomeric alpha-synuclein, an abnormal form of the protein whose aggregates are implicated in nerve damage in PD.

The test administered is based on a Schirmer’s test, which is used in ophthalmology to measure tear production. A strip of paper is placed in the lower eyelid pouch to collect tears, which the researchers then can analyze using commercially available assays.

Dr. Lew and his colleagues found levels of the oligomeric form of alpha-synuclein to be significantly greater in PD patients than they were in controls: an average of 1.45 ng/mg of tear protein, compared with 0.27 ng/mg in controls (P = .0007).

Total alpha-synuclein was decreased significantly in PD patients relative to healthy controls.

Pages

Recommended Reading

New DBS device gains approval for Parkinson’s disease
MDedge Neurology
Corynebacterium in the gut can trigger Parkinson’s disease
MDedge Neurology
Low caffeine in blood could be marker of early Parkinson’s
MDedge Neurology
FDA cites manufacturer of autologous stem cells for regulatory, manufacturing missteps
MDedge Neurology
Mutations on LRRK2 gene modify risks for both Crohn’s and Parkinson’s
MDedge Neurology
Mass Psychogenic Illness: Risk Factors and Treatment
MDedge Neurology
Mogamulizumab active in HTLV-1–associated myelopathy
MDedge Neurology
New Drug Technology Could Treat Huntington’s Disease
MDedge Neurology
Gait freezing relieved by spinal cord, transcranial direct-current stimulation
MDedge Neurology
25 Years of Movement Disorders
MDedge Neurology